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Introduction: Mutations in isocitrate dehydrogenase genes IDH1 or IDH2 are frequent in glioma, and IDH mutation
status is a strong diagnostic and prognostic marker. Current IDH mutation screening is performed with an
immunohistochemistry (IHC) assay specific for IDH1 R132H, the most common mutation. Sequencing is recommended
as a second-step test for IHC-negative or -equivocal cases. We developed and validated a new real-time quantitative
polymerase chain reaction (PCR) assay for single-step detection of IDH1 R132H and 11 rare IDH1/2 mutations in
formalin-fixed paraffin-embedded (FFPE) glioma samples. Performance of the IDH1/2 PCR assay was compared to IHC
and Sanger sequencing.
Results: The IDH1/2 PCR assay combines PCR clamping for detection of 7 IDH1 and 5 IDH2 mutations, and
Amplification Refractory Mutation System technology for specific identification of the 3 most common mutations (IDH1
R132H, IDH1 R132C, IDH2 R172K). Analytical sensitivity of the PCR assay for mutation detection was <5% for 11/12
mutations (mean: 3.3%), and sensitivity for mutation identification was very high (0.8% for IDH1 R132H; 1.2% for IDH1
R132C; 0.6% for IDH2 R172K). Assay performance was further validated on 171 clinical glioma FFPE samples; of these,
147 samples met the selection criteria and 146 DNA samples were successfully extracted. IDH1/2 status was successfully
obtained in 91% of cases. All but one positive IDH1 R132H-IHC cases were concordantly detected by PCR and 3 were
not detected by sequencing. Among the IHC-negative cases (n = 72), PCR detected 12 additional rare mutations
(10 IDH1, 2 IDH2). All mutations detected by sequencing (n = 67) were concordantly detected by PCR and 5/66
sequencing-negative cases were PCR-positive (overall concordance: 96%). Analysis of synthetic samples representative
of the 11 rare IDH1/2 mutations detected by the assay produced 100% correct results.
Conclusions: The new IDH1/2 PCR assay has a high technical success rate and is more sensitive than Sanger sequencing.
Positive concordance was 98% with IHC for IDH1 R132H detection and 100% with sequencing. The PCR assay can reliably
be performed on FFPE samples and has a faster turnaround time than current IDH mutation detection algorithms. The
assay should facilitate implementation of a comprehensive IDH1/2 testing protocol in routine clinical practice.
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Histopathological evaluation remains the gold standard
for glioma classification [1] but the incorporation of emer-
gent molecular biomarkers has been shown to improve
diagnosis and prognosis of this heterogeneous disease. In
addition to the established 1p/19q co-deletion andMGMT
methylation, new biomarkers including IDH1/2, EGFR or
BRAF mutations and FGFR gene fusions, are increasingly* Correspondence: helene.peyro-saint-paul@qiagen.com
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unless otherwise stated.documented to play a role as diagnostic, prognostic or
predictive markers, and should progressively be intro-
duced in the diagnostic and treatment decision algorithm
for glioma [2,3].
IDH1/2 mutations are highly frequent (up to 80%) in
diffuse glioma [4-6]. Their identification in surgical neuro-
pathology samples increases diagnostic accuracy of World
Health Organization (WHO) grade II or III astrocytoma,
oligodendroglioma, oligoastrocytoma, and WHO grade IV
secondary glioblastoma (GBM) [5,7]. In addition, IDH mu-
tations have been repeatedly shown to be associated withl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 IDH1/2 mutations detected and identified* with
the IDH1/2 PCR assay
Gene Mutation Base change Cosmic ID**
IDH1 Arg132His (R132H)* 395G > A COSM28746
Arg132Cys (R132C)* 394C > T COSM28747
Arg132Ser (R132S) 394C > A COSM28748
Arg132Gly (R132G) 394 C > G COSM28749
Arg132Leu (R132L) 395G > T COSM28750
Arg132Val (R132V) 394_395 CG > GT COSM28751
Arg100Gln (R100Q) 299 G > A COSM88208
IDH2 Arg172Lys (R172K)* 515G > A COSM33733
Arg172Met (R172M) 515G > T COSM33732
Arg172Trp (R172W) 514A > T COSM34039
Arg172Ser (R172S) 516G > T COSM34090
Arg172Gly (R172G) 514A > G COSM33731
*Mutations identified by ARMS.
**www.sanger.ac.uk/genetics/CGP/cosmic.
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valuable prognostic information [8-12]. Based on these
findings, IDH1 mutation status is becoming part of the
standard diagnostic assessment of these tumors and will
likely be included in the next WHO classification of dif-
fuse gliomas [2].
In addition, IDH mutation status may predict benefit
from alkylating agent when combined with MGMT pro-
moter methylation assessment [13]. Very recently, updated
data from the RTOG 9402 trial showed that the IDH mu-
tation predicts the benefit of adjuvant chemotherapy in
grade III glioma, even in absence of 1p19q co-deletion
[14]. Recent data suggested that IDH1 mutation may also
serve as a predictive marker to guide aggressive surgical
resection of malignant astrocytomas [15].
Given the high IDH clinical relevance, stratification
according to IDH mutation should be taken into ac-
count for more effective future clinical trials [2,16]. In
addition, the discovery of IDH mutations has led to the
development of novel therapies targeted against IDH al-
terations, using selective IDH inhibitors or by reversion
of mutated-IDH induced hypermethylation with the use
of DNA methyltransferase inhibitors [17-19].
IDH1 R132H mutation represents the most common
IDH mutation (approximately 90%). Less common are the
IDH mutations within the same IDH1 codon 132 (around
7%), and in the homologous IDH2 codon 172 (approxi-
mately 3%) [20].
An algorithm for IDH mutation screening has recently
been proposed [21]. It is a two-step process implying ini-
tial search for the most common IDH1 R132H mutation
using immunohistochemistry (IHC)-based assay, followed
by DNA-based analysis on IHC-negative or -equivocal
cases. The IDH1 R132H mutation-specific antibody shows
high sensitivity and specificity [7,22], but the IHC tech-
nique can be problematic in some cases, as a result of
background staining or regional heterogeneity of IDH1
R132H protein expression [23]. Regarding DNA-based
analyses, Sanger sequencing still represents the gold
standard for the identification of somatic mutations. How-
ever, sequencing sensitivity is low (around 15-20% muta-
tion load) and this may lead to false negative results when
analyzing tumor specimens with insufficient neoplastic
cells in a background of normal cells. Moreover, this tech-
nology is also not readily available in all neuropathological
centers, and its use generally leads to additional delay in
providing a comprehensive IDH mutational status assess-
ment. Here we describe a new IDH1/2 polymerase chain
reaction (PCR) assay which was designed to detect the
most common IDH1 R132H mutation and 11 rare IDH
mutations in one single step using formalin-fixed paraffin-
embedded (FFPE) samples. Analytical studies were con-
ducted to verify its performance. This assay was further
validated on a large series of FFPE glioma samples todetermine the reliability of the method in a routine clinical
setting, by comparing IDH1/2 mutation analysis with IHC
and Sanger sequencing.
Materials and methods
IDH1/2 one-step quantitative PCR assay
PCR-clamping was used for the qualitative detection of 6
mutations within IDH1 codon 132 (the 2 major R132H and
R132C mutations, and 4 “IDH1-other”: R132G, R132S,
R132L, R132V), one within IDH1 codon 100 (R100Q) and
5 within IDH2 codon 172 (the major R172K and 4 “IDH2-
other”: R172M, R172W, R172S, R172G). Amplification Re-
fractory Mutation System (ARMS) PCR technology was
combined to selectively identify the most frequent IDH1
R132H/R132C and IDH2 R172K mutations (Table 1).
The therascreen IDH1/2 RGQ PCR kit was used follow-
ing manufacturer’s instructions (Qiagen). The test con-
sisted in 9 separate amplification reactions: (i) 3 total
amplification reactions (“Total IDH1 R132”, “Total IDH2
R172” and “Total IDH1 R100”), (ii) 3 mutation amplifica-
tion reactions of IDH1 codon 132 (“IDH1 R132 Mut”),
IDH1 codon 100 (“IDH1 R100 Mut”) and IDH2 codon
172 (“IDH2 R172 Mut”), and (iii) 3 mutation-specific amp-
lification reactions of IDH1 R132H (“IDH1 Mut R132H”),
IDH1 R132C (“IDH1 Mut R132C”) and IDH2 R172K
(“IDH1 Mut R172K”). Total reaction mixes for (i) con-
tained primers and probes amplifying both wild-type
(WT) and IDH-mutated target sequences. Mutation detec-
tion reaction mixes for (ii) combined specific primers and
probes to amplify both mutated and WT target sequences,
plus a WT-specific 3’P-blocked oligonucleotide preventing
elongation (PCR clamping). Mutation identification for
(iii) was achieved by allele-specific amplification using
ARMS (Figure 1).
Figure 1 Principle of the IDH1/2 PCR assay. Total reaction mixes (top) The total Primers and Probe Mixes (PPM-Total) used primers and probes
to amplify both mutated and wild-type (WT) target sequences. Mutation detection reaction mixes (middle) The mutation detection primers and
probe mixes combined primers and probes, to amplify both mutated and WT target sequences, plus an oligonucleotide, 3'-blocked with the
addition of a phosphate group (3’-Oligo-P) to prevent elongation (PCR clamping), which was specific to the WT target sequence. When the PCR
template contained the WT sequence, the 3'-Oligo-P bound preferentially over the PCR primer binding due to higher affinity. There was no or
low extension by the DNA polymerase and no or low amplification was observed. When a mutated sequence was present, PCR primer bound
preferentially over the 3'-Oligo-P and amplification proceeded. Mutation identification reaction mixes (bottom) Allele-specific amplification was
achieved by ARMS® (Amplification Refractory Mutation System), which exploits the ability of the DNA polymerase to distinguish between a match
and a mismatch at the 3' end of a PCR primer. When the PCR primer fully matched, the amplification proceeded with full efficiency. When the
3' base was a mismatch, only low-level background amplification occurred. The same principle shown on the figure to detect IDH1 R132H applied
for IDH1 R132C and IDH2 R172K.
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DNA using the Rotor-Gene Q 5-plex HRM instrument
(Qiagen). Run controls (positive, negative and no template
control) were assessed to ensure that acceptable Ct values
were met and that the reactions were performed correctly.
Each sample was processed once per PCR run.
Sample ΔCt values were calculated as the difference be-
tween the mutation assay Ct and respective total assay Ct
from the same sample. Samples were classified as mutation-
positive if the ΔCt value was less than or equal to the ΔCt
cut-off value of the respective mutation assay.
Determination of the cut-off values of the assay
Limit of Detection (LOD), defined as the lowest amount
of mutant DNA in a WT DNA background, was based on
the “precision profile approach” following the CLSI EP17-A2 guideline [24]. A sample set was developed by mixing
synthetic IDH mutant DNA with WT genomic DNA to
correspond to 5 IDH1/2 mutation positive percentages (2,
5, 10, 15 and 20%). In total, 30 to 110 measurements were
made per mutation type and mutation percentage. Each
sample was run in duplicate, over 5 days on 3 different in-
struments and with 3 different lots of IDH1/2 therascreen
kits, leading to a total of 2250 ΔCt measurements.
For each mutation LOD, the associated mutation per-
centage was estimated by fitting a non-linear model be-
tween ΔCt values and mutant percentage.
IDH1/2 quantitative PCR assay repeatability and
reproducibility
The precision of the therascreen IDH1/2 kit was deter-
mined using a protocol based on the CLSI EP05-A2 [25].
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repeatability (Sr), between-runs reproducibility (Srun),
within and between-days and precision of the assay (Stot).
Synthetic mutant samples were used for this evaluation:
WT genomic DNA from clinical glioma FFPE samples was
spiked in 3 mastered proportions (5, 10 and 30% mutant
copies) with either R100Q, R132C, R132H or R172K plasmid
mutant DNA. Corresponding WT DNA (0%) was also
tested. Each sample was tested 40 times in duplicate i.e. 80
ΔCt measurements. Runs were performed by 3 operators
over 10 days, on 2 RGQ instruments, with 3 different lots of
IDH1/2 therascreen kits leading to a total of 2240 ΔCt mea-
surements. A variance Component Analysis (fully nested
Model II ANOVA) was performed on ΔCt values to estimate
the different sources of variability for each mutation test.
Glioma clinical samples
A total of 171 FFPE clinical tumor samples were collected.
In total, 121 samples were retrospectively collected from
the Pitié-Salpêtrière Hospital (n = 19) and the Mayo Clinic
(n = 102) tumor banks and 50 additional FFPE samples
were collected from commercial tumor banks. All FFPE
sections were reviewed by local neuropathologists for
diagnosis of glioma and assessment of neoplastic cellular-
ity. Samples selection criteria were based on age of the
samples (<10 years old), tissue area (≥50 mm2) and neo-
plastic cellularity (sections with ≥40% tumor cells).
Synthetic mutant-IDH DNA samples
Synthetic samples representative of each of the 6 minor
IDH1 and 5 IDH2 mutations (Table 1) were prepared at
2 dilutions (30 and 40%) by mixing mutant-IDH syn-
thetic DNA into WT IDH genomic DNA. The samples
were processed similarly to clinical samples.
Immunochemistry
The presence and extent of tumor was assessed on H&E
slides. Immunohistochemical staining for mutant IDH1
was performed using the anti-human IDH1 R132H mouse
monoclonal antibody DIA clone H09 (Dianova, Germany)
at a dilution of 1:100. Pretreatment of slides with Cell Con-
ditioner 1 (EDTA) MILD using the Ventana BenchMark
XT stainer system was followed by incubation with the pri-
mary antibody for 32 minutes at 37°C, which was then de-
tected using Ventana UltraView detection with Ventana
DAB. Hematoxylin counterstain was performed with the
Leica ST 5020 apparatus. Positive and negative controls
were performed using specimens previously validated.
DNA extraction from FFPE samples
DNA was extracted from 10 μm FFPE sections using
the QIAamp DNA FFPE Tissue kit (Qiagen) following
instructions for use of the therascreen IDH1/2 RGQ
PCR kit (Qiagen).IDH1 and IDH2 sequencing
Bidirectional Sanger sequencing was performed centrally
(Qiagen, Hilden). Fragments of 129 base pairs (bp) for
IDH1 codon 132 and 150 bp length for IDH2 codon 172
were amplified using primers previously described [21].
A fragment containing IDH1 codon 100 was amplified
using the following primers: 5’-AAGGATGCTGCAGA
AGCTATAA-3’ (forward) and 5’-CCATAAGCATGACG
ACCTATGA-3’ (reverse). Briefly, PCR was performed in a
total volume of 60 μL using 15 ng of DNA and Taq Poly-
merase Platinium in standard PCR buffer conditions. Ini-
tial denaturation at 94°C for 2 minutes was followed by
35 cycles of 94°C for 30 secondes, 55°C for 30 secondes
and 68°C for 30 secondes. PCR products were purified using
the QIAquick 96 PCR Purification kit (Qiagen, Hilden).
The purified PCR products (1.5 μL) were sequenced
using Applied Biosystems Big Dye 3.1 dideoxy chain
termination sequencing chemistry in conjunction with
fluorescent-based capillary sequencers (Model 3730xl
Applied Biosystems Division of Perkin Elmer, Foster
City, California, USA) for electrophoresis, data collection
and base calling.
Pyrosequencing for detection of IDH1 codon 132 and
IDH2 codon 172 mutations was performed as previously
described [26]. Locked Nucleic Acid (LNA) Sanger se-
quencing was performed in a separate reaction by amplify-
ing the mutation hotspot regions using the pyrosequencing
PCR primers and LNA (+T +A+G+G+T+C+G+T+
C+A+/3InvdT/) at the final concentration of 70 nM. The
PCR product was sequenced using BigDye Terminator v1.1
Sequencing kit (Applied Biosystems; Foster City, CA, USA).Statistical analyses
The main objective of the clinical validation study was to
calculate the Positive Percent Agreement (PPA) first, be-
tween the IDH1/2 PCR test and IDH1 R132H IHC, and
secondly, between the IDH1/2 PCR test and Sanger se-
quencing. For both comparisons, the aim was to obtain a
PPA of at least 90% with a target of 95%, with a lower
boundary (Lbound) of 95% confidence interval (CI) ≥90%.
The PPA between the PCR test and the reference
methods (IHC and Sanger sequencing) was calculated as
the percentage of true positive (TP) i.e. the percentage of
cases detected as positive by both the IDH1/2 PCR test
and the reference method, according to the following for-
mula: PPA = (100×TP)/(TP + FN), where FN were false-
negative cases i.e. negative by PCR when reference method
was positive.
Secondary objectives were to calculate the Negative
Percent Agreement (NPA) defined as NPA = (100×TN)/
(TN + FP) and overall agreement (OA) defined as OA =
(TP + TN)/(TP + TN + FP + FN), where TN and FP were
true negative and false positive cases, respectively.
Figure 2 Sensitivity of the IDH1/2 PCR assay for the 12 detected and 3 identified IDH1/2 mutations. The sensitivity defined as the lowest
amount of mutant DNA in a background of wild-type DNA was indicated for each of the 12 IDH1/2 mutations detected with the PCR IDH1/2 kit.
The cut-off values were derived from a total of 2250 ΔCt measurements. Sensitivity varied across mutations from 0.6% to 15% with a mean of
3.3% (red dotted line). Limit of Detection was <5% for 11/12 mutations and ≤3% for 9 of them.
Catteau et al. Acta Neuropathologica Communications 2014, 2:58 Page 5 of 12
http://www.actaneurocomms.org/content/2/1/58Results
Determination of sensitivity
The IDH1/2 assay was based on a combination of PCR-
clamping and ARMS technology and can detect 12
IDH1/2 mutations (Table 1). Assay sensitivity was there-
fore estimated for each mutation, by LOD using mixed
mutant IDH DNA with WT genomic DNA at 5 muta-
tion percentages i.e. 2, 5, 10, 15 and 20%. Sensitivity var-
ied according to mutations, ranging from 0.6% to 15%,
(Figure 2 and Additional file 1: Table S1) with a mean of
3.3%. Sensitivity results are shown as supplementary
data (Additional file 2: Figure S1). Reproducible and reli-
able mutation detection was achieved at a concentration
of mutant DNA below 5% for 11/12 mutations and ≤3%







Figure 3 Distribution of the clinical glioma samples by tumor type (W
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IDH2 R172K (Figure 2 and Additional file 1: Table S1).
Repeatability and reproducibility
IDH WT and mutant samples were tested at 3 different
mutant allele burden (5, 10 and 30%) and precision per-
formance of the IDH1/2 PCR assay was established on a
total of 2240 measurements (see Materials and Methods).
High precision was demonstrated for the 3 mutant sample
levels and WT, with at least 99% correct mutation calls for
all mutation assays across multiple lots, platforms and op-
erators for both within- and between-run experiments.
Estimates of variance for each tested mutant and WTsam-
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Figure 4 IDH1/2 PCR assay experimental flowchart: technical
success rate. Out of the 147 formalin-fixed paraffin-embedded
glioma clinical samples meeting the selection criteria, one DNA
extraction failed. From the remaining samples, IDH1/2 PCR assay
results were successfully obtained for most of the samples (91%).
Successful tests were achieved on all samples (n = 103) originating
from academic centers.
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Performance of the assay was established on 171 retro-
spectively tested FFPE clinical glioma samples collected
in 3 different sources: the Pitié-Salpêtrière Hospital, the
Mayo Clinic and commercially available. Twenty-four
samples did not meet the selection criteria (see Materials
and Methods): for 2 cases, diagnosis of glioma was not
confirmed; 17 samples were more than 10 years old and 5
samples contained less than 40% tumor cells. Histological
distribution of the tumor samples reflected distribution
observed in clinical routine with a predominance of glio-
blastomas (n = 61, 41%). The other samples were astro-
cytomas (n = 22, 15%), anaplastic astrocytomas (n = 25,
17%), oligodendrogliomas (n = 3, 2%), anaplastic oligo-
dendrogliomas (n = 4, 3%), oligoastrocytomas (n = 12, 8%),
and anaplastic oligoastrocytomas (n = 20, 14%) (Figure 3).Table 2 Agreement between IHC and IDH1/2 PCR assay
for the detection of IDH1/2 R132H mutation
IHC
R132H positive R132H negative Total
IDH1/2 PCR
R132H 60 0 60
Non-R132H 1 72 73
Total 61 72 133
IHC: Immunohistochemistry; PCR: Polymerase chain reaction.Out of the 147 FFPE samples which met the selection
criteria, DNA extraction failed for one sample, while an
IDH1/2 result was successfully obtained by the PCR test
in 91% of cases (133/146). Different technical success rates
were observed according to the origin of the samples with
100% technical success rate on samples from academic
centers (103/103) and 70% on commercial samples
(30/43) (Figure 4).
Clinical validation: comparison of IDH1/2 assay with IDH1
R132 immunochemistry and Sanger sequencing
To demonstrate the accuracy of the IDH1/2 PCR assay
on clinical routine glioma samples, we examined the
concordance between the IDH1/2 PCR results and re-
sults obtained with the current IDH1 R132H immuno-
staining and Sanger sequencing technologies. Out of the
133 samples successfully assessed by PCR, 61 (46%) were
WT and 72 (54%) contained an IDH1/2 mutation. Out
of the 72 mutated specimens, 60 (83%) carried the most
common IDH1 R132H mutation, while the 12 remaining
cases carried rare IDH mutations: IDH1 R132C in 3
cases, IDH1 R132-other in 7 cases, and IDH2 R172K in
1 case and IDH2 R172-other in 1 case. Using the IHC-
based assay, 61 cases out of the 133 were scored as IDH1
R132H-positive. All but one IHC-positive cases were con-
cordantly detected as IDH1 R132H by the PCR test and
none of the remaining 72 IHC-negative cases were de-
tected as IDH1 R132H-positive by PCR (Table 2), which
translated into an OA of 99% [CI 95%, 95.9-99.9] between
PCR and IHC (98.4% positive agreement [CI 95%, 91.3-
99.7], 100% negative agreement [CI 95%, 94.9-100]).
When evaluating the 133 specimens by Sanger sequen-
cing, the same mutations were detected by both Sanger se-
quencing and PCR in 67 cases (58 IDH1 R132H, 2 IDH1
R132C, 6 IDH1 R132-other and 1 IDH2 R172K), while the
PCR assay detected 5 additional mutated cases (2 IDH1
R132H, 1 IDH1 R132C, 1 IDH1 R132-other and 1 IDH2
R172-other) (Tables 3 and 4), resulting in an OA of 96%
[CI 95%, 91.5-98.4] between PCR and Sanger sequen-
cing with a 100% positive agreement [CI 95%, 94.6-100]
and 92% negative agreement [CI 95%, 83.5-96.7]. Prede-
fined concordance targets for both PCR-IHC and PCR-
Sanger comparisons were therefore met. Complete analysisTable 3 Agreement between Sanger sequencing and IDH1/








IDH1/2 mutated 67 5 72
IDH1/2 non-mutated 0 61 61
Total 67 66 133
PCR: Polymerase chain reaction.
Table 4 Number and types of IDH 1/2 mutations detected by IHC, Sanger sequencing and PCR (n = 133)
IDH1/2 WT IDH1 mutated IDH2 mutated % Mutated cases
R132H R132C R132 OTHER R100 R172K R172 OTHER
IHC 72 61 NA NA NA NA NA 46
Sanger sequencing 66 58 2 6* 0 1 0 50
IDH1/2 PCR 61 60 3 7 0 1 1 54
IHC: Immunohistochemistry; PCR: Polymerase chain reaction; WT: Wild-type; NA: not applicable.
*3 R132S; 2 R132G; 1 R132L.
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Sanger sequencing is shown in supplementary Additional
file 1: Table S3.
Three IHC-positive cases were not reported positive by
Sanger sequencing, including the PCR-negative case. Out
of the 72 IHC-negative cases, Sanger sequencing identified
9 rare mutations (12%; 8 IDH1, 1 IDH2) while PCR identi-
fied 12 rare mutations (17%; 10 IDH1, 2 IDH2) (Table 4).
The 6 cases discordant across the techniques for their
identification of IDH mutation status were further investi-
gated (Table 5). Case #1 (Figure 5), a sample of commer-
cial origin, was IDH1 R132H IHC-positive but mutation
negative by PCR and Sanger sequencing. We used 2 other
techniques more sensitive than Sanger Sequencing: pyro-
sequencing followed by LNA-sequencing to further
analyze this case. The IDH1 R132H mutation was not
identified by any of these additional techniques. Conse-
quently, based on the consistency of results obtained with
PCR, Sanger sequencing, pyrosequencing and LNA-
sequencing, it was likely that the mutation detected by
IHC was a false-positive result.
Cases #2 and #3 were identified as IDH1 R132H posi-
tive according to both IHC and PCR testing, and nega-
tive with Sanger sequencing. Review of the IHC R132H
FFPE slide by a second pathologist confirmed the unam-
biguous IDH1 R132H positive IHC result. Quantitative
PCR analysis revealed a low mutant allele percentage of
15% and 10% in cases #2 and #3, respectively. These per-
centages were below the Sanger sequencing sensitivity
threshold (typically around 20% [27,28]). ConsequentlyTable 5 Analysis of the IHC/PCR and PCR/Sanger sequencing
Case IHC IDH1/2 PCR Sanger sequencing Pyros
# 1 (commercial) Pos WT WT
# 2 Pos R132H WT
# 3 Pos R132H WT
# 4 (commercial) Neg R132C WT R
# 5 (commercial) Neg R132 WT
# 6 Neg R172 WT
IHC: Immunohistochemistry; PCR: Polymerase chain reaction; WT: Wild-type; Pos: Po
*PCR test result close to LOD value.this technical limit was likely to prevent mutation detec-
tion in these particular cases by Sanger sequencing.
Similarly, in case #4 identified as IDH1 R132C by PCR
but WT by Sanger sequencing, a low mutant allele per-
centage (14%) was the probable source of conflicting re-
sults between these 2 tests as the mutation was also
detected by pyrosequencing (Figure 6).
Cases #5 and #6 were found to be IDH1 R132 and
IDH2 R172 PCR-positive respectively, but were not de-
tected by IHC or Sanger sequencing. Pyrosequencing
and LNA sequencing confirmed the absence of muta-
tion in both cases, thereby indicating probable false
PCR-positive results. The PCR Ct values of these 2 cases
were close to the cut-off values of the respective muta-
tions (data not shown). In order to eliminate a technical
issue, PCR runs were repeated twice on cases #5 and #6
and the results indicated an IDH WT status. The first
PCR results could therefore be considered as false-
positive.Validation of rare IDH1/2 mutations using
synthetic samples
As the likelihood of having a significant representation of
rare IDH1/2 mutations in the clinical cohort was low, syn-
thetic samples representative of all 11 rare mutations were
prepared. Each rare mutation was tested at 2 mutant allele
percentages (30 and 40% of mutant DNA mixed with IDH
WTgenomic DNA). All mutations were correctly detected
by the PCR assay in the 22 samples tested.discordant cases
equencing LNA-sequencing Result Conclusion
WT WT WT IHC False-Pos
- - R132H Low Mutant Allele% (15%)
- - R132H Low Mutant Allele% (10%)
132C - R132C Low Mutant Allele% (14%)
WT WT WT PCR False-Pos*
WT WT WT PCR False-Pos*
sitive; Neg: Negative; LOD: limit of detection.
Figure 5 Discordant case # 1. Case #1 stained IDH1 R132H positive by immunochemistry but was found WT for the IDH1 codon 132 (CGT) by
Sanger sequencing, by pyrosequencing and with the IDH1/2 PCR assay a H&E slide. b IHC using the anti-human IDH1 R132H mouse monoclonal
antibody DIA clone H09. c Sanger sequencing. d pyrogram indicating an allele frequency of 7%, thus below the cutoff for mutation≥ 15%. e, f
IDH1/2 PCR assay combining PCR-clamping (e) and ARMS (f): the red horizontal lines correspond to the threshold used to determine Ct. Total
copies of IDH1 (WT ±mutated) are amplified with the total amplification reaction (red curves) but without further amplification by PCR-Clamping
(blue curve) or by ARMS with specific R132H primers (green curve), indicating the absence of any mutation within IDH1 codon 132.
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We developed a novel PCR assay for the detection of 12
IDH1/2 mutations in one single step. A fast and reliable
IDH mutation assay easy to implement in daily practice
is highly desirable, given the diagnostic and prognostic
significance of IDH mutations in diffuse glioma of low
and intermediate grade (WHO grade II & III) as well as
in secondary GBM (WHO grade IV). Testing for the
presence of an IDH1/2 mutation is now considered by
international guidelines for glioma management [29,30].
Very recently, the predictive use of IDH mutations hasbeen confirmed in grade III glioma [14]. There is also
an increasing interest in the development of IDH-
targeted therapies. Newly developed mutated-IDH se-
lective inhibitors have already demonstrated therapeutic
effect in preclinical models [17] and an alternative ap-
proach whereby pathologic DNA-methylation is tar-
geted, has led to tumor control in IDH mutant cells
[18,19]. Consolidation of these promising results in fu-
ture clinical studies will imply identification of patients
carrying specific IDH mutations with a reliable compa-
nion diagnostics test.
Figure 6 Discordant case #4. Case #4 was IDH1 R132H negative by IHC and was identified as wild-type by Sanger sequencing for IDH1 codon
132. The IDH1/2 PCR assay identified an IDH1 R132C mutation which was confirmed by pyrosequencing. a H&E slide. b IDH1 R132H IHC positive
staining. c Sanger sequencing. d the pyrogram indicates the presence of the IDH1 R132C mutation (TGT) at a low allele frequency (around 15%)
suggesting that the sample contained low tumor cell content. e PCR-clamping: the difference between the IDH1 PCR-clamping mutation assay Ct
(blue curve) and total assay Ct (red curve) is inferior to the cutoff value (ΔCt = 31.87 - 27.49 = 4.38 < 5.34) indicating the presence of a mutation
within IDH1 codon 132. f ARMS: the difference between the total assay Ct (red curve) and the IDH1 R132C ARMS assay Ct (green curve) is inferior
to the cutoff value (ΔCt = 31.20 – 27.49 = 3.71 < 7.14) indicating presence of the IDH1 R132C mutation.
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tion, and various molecular techniques are used to assess
the IHC-negative cases, leading to a two-step diagnostic
algorithm with possibly long timelines to complete a full
IDH profiling. With the Sanger sequencing, multiple DNA-
based assays have been adapted for the detection of IDH
mutations, including restriction length fragment poly-
morphism gel electrophoresis, PCR and endonuclease
restriction, allele-specific polymerase chain reaction, py-
rosequencing, high resolution melting (HRM) or cold-
PCR HRM [31-36].These methods present pros and cons in terms of ease
of use, rapidity, and sensitivity performance. The majo-
rity of published assays targets the most frequent IDH1
R132 mutations but they are not designed to detect
other rare ones including those within that same codon
132, the IDH1 R100 mutations or the IDH2 mutations.
Therefore we developed an alternative assay for rapid
(only 5 hours from DNA extraction to data acquisition)
and comprehensive analysis of the 12 clinically IDH1/2
mutations reported to date, with a single-step design
compatible with easy implementation in routine clinical
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performance of a new test is critical before implementa-
tion in a pathology laboratory. In this study, we validated
the performance of this new IDH1/2 PCR assay on a
large cohort of FFPE glioma samples collected less than
10 years ago and on synthetic samples mimicking all 11
rare IDH1/2 mutations. Out of the 147 FFPE tested sam-
ples, the overall technical success rate of the PCR assay
was 91%, reaching 100% on the 103 samples collected
from academic centers. The technical success rate ob-
tained on the remaining 43 commercial samples (DNA
extraction failed from one sample) was lower (70%); this
was probably due to a poor formalin fixation of this spe-
cific FFPE sample series, therefore impacting on the
sample quality.
The assay showed a higher sensitivity than Sanger se-
quencing which typically detects levels as low as
around 20% of mutant allele load. Without any mutant
DNA enrichment before the IDH1/2-specific PCR, the
test showed high analytical sensitivity with detection of
mutant allele frequency, ranging from 0.6% for IDH2
R172K to below 5% for all mutations except for the
rare IDH2 R172S one. Moreover, the precision study
demonstrated that results for the mutation detection
were highly reproducible and reliable including for
mutant allele frequencies of 5%.
Out of the 133 clinical samples with a successful
PCR IDH determination, IDH1/2 mutations were de-
tected in 54% of cases. The frequency of mutations by
histological subtype was similar to previous reports
from large series [5] with 13% of mutations identified
in primary GBMs as opposed to 83% in the other sub-
types. We further examined the PCR test accuracy by
comparing, in a blind manner, the results obtained
from the 133 clinical FFPE samples to the ones from
IDH1 R132H-IHC and Sanger sequencing, which are
the 2 main clinical diagnostic technologies recom-
mended in the current algorithms for IDH testing.
Overall concordance for IDH1 R132H detection was
99% between PCR and IHC and 96% between PCR and
Sanger sequencing. Positive concordances were high,
with 98% between PCR and IHC and 100% between
PCR and Sanger sequencing. The high concordance of
the new PCR assay with the standard technologies
demonstrated that the test could be used reliably for
clinical diagnostics.
Regarding the agreement with IDH1 R132H-IHC, only
one case was detected as negative discordant and this
case was likely to be a false-positive IHC case as its ana-
lysis with 2 additional sensitive techniques confirmed its
PCR and Sanger sequencing-identified IDH WT status.
This highlights the need to ensure high quality in IHC
testing when used for routine clinical diagnostic [37].
The number of cases (5 identified in total) withconflicting results from the IDH1/2 PCR assay and
Sanger sequencing was less than 4%. Three of them
could be explained by a low mutant allele content
(<20%) which is below the Sanger sequencing sensitivity
and therefore the mutation could not be detected using
this technique. This further illustrates that if sensitivity
of sequencing is generally not an issue when analyzing
tumor samples with high content of neoplastic cells, it
can become a limiting factor in the absence of macro-
dissection for samples with a low tumor cellularity, lead-
ing to false negative results.
Overall, only 2 false-positive PCR results out of the
133 samples tested here were identified by comparison
of IHC, Sanger sequencing, pyrosequencing and LNA-
sequencing, which consistently established a WT IDH
status for these 2 samples. Repeated PCR tests on these
samples indicated a WT IDH status, supporting the hy-
pothesis that the false-positive result from the first run
might have come from an experimental error.
Additional synthetic samples were further analyzed in
order to confirm the correct detection of all 11 rare mu-
tations from the PCR assay and this analysis indicated
100% correct calls, further validating the performance
of the assay.
Interestingly, a new dinucleotide deletion/insertion mu-
tation has been reported since the design of this assay
[38]. Since this newly identified mutation is localized
within the codon 132 of the IDH1 gene, the assay design
and more specifically the clamping reaction, may allow its
detection. It will be of interest to confirm this on synthetic
samples reproducing this mutation and then on clinical
FFPE samples if available.
Conclusions
In summary, we have developed a new PCR-based
assay which enables rapid and simple detection of the
major IDH1 R132H mutation and of 11 rarer IDH1/2
ones in FFPE glioma samples. The test is designed as a
single-step PCR procedure combining clamping and
ARMS. We have established here the high sensitivity
and reliability of this new assay and validated it on 171
FFPE clinical samples, indicating that the test fulfilled
both analytical and clinical performance required for
implementation in clinical practice. The PCR test
could be used as a rapid and robust novel tool in the
clinical assessment of diffuse gliomas as well as in
selecting patients suitable for clinical trials.
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